{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rosacea/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 3c3b777e-8284-4f76-a76e-b27d28d686e7 --><h2>Changes</h2><!-- end field 3c3b777e-8284-4f76-a76e-b27d28d686e7 -->","summary":null,"htmlStringContent":"<!-- begin item ffd9750f-a710-4361-83fc-28da0d654d18 --><!-- begin field f3a663ec-e86b-4a22-b20e-0bee46aec5cf --><p><strong>January 2021 </strong>— minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field f3a663ec-e86b-4a22-b20e-0bee46aec5cf --><!-- end item ffd9750f-a710-4361-83fc-28da0d654d18 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","lastRevised":"Last revised in January 2021","chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","fullItemName":"Management","slug":"management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"36d59651-e45f-5540-9bec-434cf23a3c58","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e3e6b155-5470-4694-b8aa-b49f8cb0423c --><h3>Previous changes</h3><!-- end field e3e6b155-5470-4694-b8aa-b49f8cb0423c -->","summary":null,"htmlStringContent":"<!-- begin item 3689c082-719a-47b3-ad90-a14cc4848a37 --><!-- begin field 1bf4d97c-7f9d-4bd6-80a9-c78561eb9ef1 --><p><strong>May to June 2020 </strong>— reviewed. A literature search was conducted in May 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic name has been changed from <em>Acne rosacea</em> to <em>Rosacea</em>, in line with current literature. The topic has undergone minor restructuring. A new section on Assessment has been added to the Diagnosis section. The sections on Self-care advice and Follow-up have been deleted and the content has been incorporated into the Management node. The sections on the diagnosis and management of rosacea have been updated to recommend a phenotype approach based on individual clinical features, rather than the previous subtype approach, in line with international consensus publications from the ROSacea COnsensus (ROSCO) panel [Schaller, 2017; Schaller 2020]. The option of prescribing topical ivermectin in primary care has been included, and the choice of oral antibiotics has been amended, in line with current literature. The Prescribing information section has been updated.</p><p><strong>October 2018 </strong>— minor update. The adverse effects section of the drug metronidazole has been updated in the section on Prescribing information.</p><p><strong>June 2017 </strong>— minor update. Text added on the contraindications and adverse effects of brimonidine gel following the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin</em> (2017).</p><p><strong>November 2016 </strong>— minor update. Information added on the risk of exacerbation of rosacea with brimonidine gel. </p><p><strong>December 2015 to January 2016 </strong>— reviewed. A literature search was conducted in December 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has been updated in line with a Cochrane systematic review <em>Interventions for rosacea</em> [Van Zuuren, 2015], and topical brimonidine 0.5% gel has been added as a treatment option. Minor restructuring of the topic has also been undertaken.</p><p style=\"text-align: justify;\"><strong>September 2012</strong> — reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p style=\"text-align: justify;\"><strong>October 2009</strong> — minor update. Text updated to include doxycycline 40 mg modified-release capsules, which have been recently licensed in the UK for the treatment of rosacea. Issued in October 2009.</p><p style=\"text-align: justify;\"><strong>May to August 2008</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p style=\"text-align: justify;\"><strong>May 2007 </strong>— minor update. Topical azelaic acid 15% gel has recently been launched and is licensed for use in papulopustular rosacea. The prescription for topical azelaic acid 20% cream (unlicensed for this indication) has been substituted for azelaic acid 15% gel (licensed). Issued in May 2007.</p><p style=\"text-align: justify;\"><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p style=\"text-align: justify;\"><strong>March 2005</strong> — written. Validated in June 2005 and issued in July 2005.</p><!-- end field 1bf4d97c-7f9d-4bd6-80a9-c78561eb9ef1 --><!-- end item 3689c082-719a-47b3-ad90-a14cc4848a37 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}